🇺🇸 FDA

Intelligence · Clinical Pipeline

Cognition Therapeutics Pipeline

All ClinicalTrials.gov programs at Cognition Therapeutics — phase, modality, and trial IDs.

Programs
33

Quick answer

Cognition Therapeutics has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Psychosis

    phase 3 small molecule active

    1 trial

  2. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Treatment Resistant Psychosis

    phase 3 small molecule active

    1 trial

  3. Vortioxetine

    COGNITION THERAPEUTICS INC

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  4. Active Comparator CT1812

    COGNITION THERAPEUTICS INC

    Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial

  5. Active Treatment- CT1812 100 mg

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  6. Autobiographical Memory Flexibility (MemFlex) training

    COGNITION THERAPEUTICS INC

    Major Depressive Disorder

    phase 2 other completed

    1 trial

  7. C105

    COGNITION THERAPEUTICS INC

    Cognition Disorders

    phase 2 small molecule completed

    1 trial

  8. CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    3 trials

  9. CT1812

    COGNITION THERAPEUTICS INC

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  10. CT1812

    COGNITION THERAPEUTICS INC

    Early Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  11. CT1812

    COGNITION THERAPEUTICS INC

    Dementia With Lewy Bodies

    phase 2 small molecule completed

    1 trial

  12. CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  13. Dexmedetomidine

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  14. Golexanolone Placebo Capsules, oral capsules, soft, GR3027 10 mg

    COGNITION THERAPEUTICS INC

    Primary biliary cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  15. Memory Flexibility Training

    COGNITION THERAPEUTICS INC

    Major Depressive Disorder

    phase 2 other completed

    1 trial

  16. Oxytocin nasal spray

    COGNITION THERAPEUTICS INC

    Oxidative Stress

    phase 2 small molecule completed

    1 trial

  17. Oxytocin nasal spray

    COGNITION THERAPEUTICS INC

    Cold Exposure

    phase 2 small molecule completed

    1 trial

  18. Psilocybin

    COGNITION THERAPEUTICS INC

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  19. The Modular Protocol for Mental Health

    COGNITION THERAPEUTICS INC

    Major Depressive Disorder

    phase 2 other completed

    1 trial

  20. Vortioxetine

    COGNITION THERAPEUTICS INC

    Post-COVID-19 Condition

    phase 2 small molecule completed

    1 trial

  21. golexanolone

    COGNITION THERAPEUTICS INC

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  22. 300 mg [C14] CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  23. CT1812

    COGNITION THERAPEUTICS INC

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  24. CT1812

    COGNITION THERAPEUTICS INC

    Cognitive Impairment

    phase 1 small molecule completed

    1 trial

  25. Itraconazole

    COGNITION THERAPEUTICS INC

    Drug Interaction

    phase 1 small molecule completed

    1 trial

  26. 24/7 EEG™ SubQ

    COGNITION THERAPEUTICS INC

    Sleep

    other completed

    1 trial

  27. Beverage powder fortified with micronutrients and Bacopa monnieri extract

    COGNITION THERAPEUTICS INC

    Cognition

    other completed

    1 trial

  28. Citalopram

    COGNITION THERAPEUTICS INC

    Antidepressive Agents, Second-Generation

    small molecule completed

    1 trial

  29. Device measurements

    COGNITION THERAPEUTICS INC

    Healthy

    other completed

    1 trial

  30. Device measurements during overnight sleep and morning wake

    COGNITION THERAPEUTICS INC

    Healthy

    other completed

    1 trial

  31. Ketone ester

    COGNITION THERAPEUTICS INC

    Hypoxia

    other active

    2 trials

  32. Nitrate enriched beetroot juice

    COGNITION THERAPEUTICS INC

    Aging

    other active

    1 trial

  33. Overnight polysomnography

    COGNITION THERAPEUTICS INC

    Alzheimer Disease, Early Onset

    other active

    1 trial

Frequently asked questions

How many pipeline programs does Cognition Therapeutics have?

33 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.